$535 Million is the total value of Opaleye Management Inc.'s 48 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 76.9% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
CMRX | Buy | CHIMERIX INC | $31,136,000 | -15.9% | 5,030,000 | +8.6% | 5.82% | -5.5% |
HROW | Buy | HARROW HEALTH INC | $29,861,000 | +2.4% | 3,285,000 | +4.6% | 5.58% | +15.1% |
SMLR | New | SEMLER SCIENTIFIC INC | $28,203,000 | – | 225,566 | +100.0% | 5.27% | – |
KNSA | Buy | KINIKSA PHARMACEUTICALS LTD | $14,921,000 | -7.3% | 1,310,000 | +13.4% | 2.79% | +4.3% |
KROS | Buy | KEROS THERAPEUTICS INC | $13,945,000 | +39.7% | 352,500 | +50.0% | 2.60% | +57.1% |
PRQR | Buy | PROQR THERAPEUTICS NV | $11,921,000 | +28.1% | 1,424,200 | +3.2% | 2.23% | +44.1% |
STRO | Buy | SUTRO BIOPHARMA INC | $10,159,000 | +10.0% | 537,800 | +8.2% | 1.90% | +23.7% |
LRMR | Buy | LARIMAR THERAPEUTICS INC | $9,602,000 | +34.4% | 832,807 | +14.4% | 1.79% | +51.1% |
CRNX | Buy | CRINETICS PHARMACEUTICALS INC | $8,464,000 | +124.0% | 402,113 | +100.6% | 1.58% | +151.8% |
TELA | Buy | TELA BIO INC | $6,054,000 | -14.7% | 443,199 | +0.6% | 1.13% | -4.1% |
OPTN | Buy | OPTINOSE INC | $4,676,000 | +22.6% | 1,558,500 | +27.1% | 0.87% | +37.7% |
FMTX | Buy | FORMA THERAPEUTICS HOLDINGS INC | $4,243,000 | -0.3% | 182,950 | +7.0% | 0.79% | +12.2% |
SRRA | Buy | SIERRA ONCOLOGY INC | $3,634,000 | +12.8% | 165,778 | +0.2% | 0.68% | +26.9% |
New | AVALO THERAPEUTICS INC | $3,181,000 | – | 1,459,400 | +100.0% | 0.59% | – | |
FOLD | New | AMICUS THERAPEUTICS INC | $3,064,000 | – | 320,800 | +100.0% | 0.57% | – |
MRUS | New | MERUS N.V. | $2,206,000 | – | 100,250 | +100.0% | 0.41% | – |
VIRX | Buy | VIRACTA THERAPEUTICS INC | $2,074,000 | -28.9% | 258,556 | +0.5% | 0.39% | -20.2% |
DTIL | New | PRECISION BIOSCIENCES INC | $1,891,000 | – | 163,900 | +100.0% | 0.35% | – |
New | AADI BIOSCIENCES INC | $1,322,000 | – | 45,020 | +100.0% | 0.25% | – | |
NCNA | New | NUCANA PLCsponsored adr | $1,237,000 | – | 479,600 | +100.0% | 0.23% | – |
AKBA | New | AKEBIA THERAPEUTICS INC | $897,000 | – | 311,300 | +100.0% | 0.17% | – |
SELB | New | SELECTA BIOSCIENCES INC | $441,000 | – | 106,000 | +100.0% | 0.08% | – |
CBAY | New | CYMABAY THERAPEUTICS INC | $420,000 | – | 115,015 | +100.0% | 0.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CODEXIS INC | 39 | Q3 2023 | 10.9% |
CHIMERIX INC | 31 | Q3 2022 | 16.4% |
XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
FIBROGEN INC | 26 | Q1 2021 | 6.8% |
BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
AXOGEN INC | 20 | Q4 2019 | 18.7% |
ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-05-10 |
4 | 2024-04-25 |
4 | 2024-04-24 |
4 | 2024-04-19 |
SC 13G/A | 2024-04-09 |
SC 13G | 2024-04-08 |
4 | 2024-03-28 |
4 | 2024-03-22 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.